5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 1 points (-0.0%) at 13,971 as of Friday, Feb. 15, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,429 issues advancing vs. 1,408 declining with 163 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is unchanged. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 5.1%, Biogen Idec ( BIIB), up 2.4%, Shire ( SHPG), up 2.3%, Novartis ( NVS), up 0.7% and AstraZeneca ( AZN), up 0.6%. On the negative front, top decliners within the sector include Agilent Technologies ( A), down 3.8%, Dr. Reddy Laboratories ( RDY), down 2.6%, Stryker Corporation ( SYK), down 1.0% and Thermo Fisher Scientific ( TMO), down 1.0%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Covidien ( COV) is one of the companies pushing the Health Care sector higher today. As of noon trading, Covidien is up $0.56 (0.9%) to $63.55 on average volume Thus far, 895,572 shares of Covidien exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $62.83-$63.60 after having opened the day at $63.14 as compared to the previous trading day's close of $62.99.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $29.9 billion and is part of the health services industry. The company has a P/E ratio of 16.1, below the S&P 500 P/E ratio of 17.7. Shares are up 9.6% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Covidien a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback